These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 27161362)

  • 1. Improved (4 Plus 2) Rituximab Protocol for Severe Cases of Mixed Cryoglobulinemia: A 6-Year Observational Study.
    Roccatello D; Sciascia S; Baldovino S; Rossi D; Alpa M; Naretto C; Di Simone D; Menegatti E
    Am J Nephrol; 2016; 43(4):251-60. PubMed ID: 27161362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature.
    Ferri C; Cacoub P; Mazzaro C; Roccatello D; Scaini P; Sebastiani M; Tavoni A; Zignego AL; De Vita S
    Autoimmun Rev; 2011 Nov; 11(1):48-55. PubMed ID: 21821153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab as a therapeutic tool in severe mixed cryoglobulinemia.
    Roccatello D; Baldovino S; Rossi D; Giachino O; Mansouri M; Naretto C; Di Simone D; Francica S; Cavallo R; Alpa M; Napoli F; Sena LM
    Clin Rev Allergy Immunol; 2008 Feb; 34(1):111-7. PubMed ID: 18270864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis.
    De Vita S; Quartuccio L; Isola M; Mazzaro C; Scaini P; Lenzi M; Campanini M; Naclerio C; Tavoni A; Pietrogrande M; Ferri C; Mascia MT; Masolini P; Zabotti A; Maset M; Roccatello D; Zignego AL; Pioltelli P; Gabrielli A; Filippini D; Perrella O; Migliaresi S; Galli M; Bombardieri S; Monti G
    Arthritis Rheum; 2012 Mar; 64(3):843-53. PubMed ID: 22147661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre study.
    Quartuccio L; Zuliani F; Corazza L; Scaini P; Zani R; Lenzi M; Tavoni A; Sebastiani M; Baldovino S; Urraro T; Saccardo F; Sbreglia C; Mazzaro C; Pioltelli P; Fraticelli P; Filippini D; Gabrielli A; Perrella O; Scarpato S; Roccatello D; Zignego AL; Ferri C; Bombardieri S; Pietrogrande M; Monti G; Galli M; De Vita S
    J Autoimmun; 2015 Sep; 63():88-93. PubMed ID: 26255249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis.
    Roccatello D; Baldovino S; Rossi D; Mansouri M; Naretto C; Gennaro M; Cavallo R; Alpa M; Costanzo P; Giachino O; Mazzucco G; Sena LM
    Nephrol Dial Transplant; 2004 Dec; 19(12):3054-61. PubMed ID: 15494358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of long-term treatment with low-dose rituximab for relapsing mixed cryoglobulinemia vasculitis.
    Colantuono S; Mitrevski M; Yang B; Tola J; Carlesimo M; De Sanctis GM; Fiorilli M; Casato M; Visentini M
    Clin Rheumatol; 2017 Mar; 36(3):617-623. PubMed ID: 28111716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature.
    Roccatello D; Sciascia S; Di Simone D; Solfietti L; Naretto C; Fenoglio R; Baldovino S; Menegatti E
    Autoimmun Rev; 2016 Jun; 15(6):529-38. PubMed ID: 26876383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab plus belimumab in non-infectious refractory cryoglobulinemia vasculitis: A pilot study.
    Saadoun D; Ghembaza A; Riviere S; Mekinian A; Boutemy J; Leroux G; Domont F; Maillard H; Vautier M; Cacoub P
    J Autoimmun; 2021 Jan; 116():102577. PubMed ID: 33248866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab in cryoglobulinemic peripheral neuropathy.
    Cavallo R; Roccatello D; Menegatti E; Naretto C; Napoli F; Baldovino S
    J Neurol; 2009 Jul; 256(7):1076-82. PubMed ID: 19263187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of low-dose rituximab for mixed cryoglobulinemia.
    Visentini M; Granata M; Veneziano ML; Borghese F; Carlesimo M; Pimpinelli F; Fiorilli M; Casato M
    Clin Immunol; 2007 Oct; 125(1):30-3. PubMed ID: 17692572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up.
    Reguiai Z; Tabary T; Maizières M; Bernard P
    J Am Acad Dermatol; 2012 Oct; 67(4):623-9. PubMed ID: 22261417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis.
    Sène D; Ghillani-Dalbin P; Amoura Z; Musset L; Cacoub P
    Arthritis Rheum; 2009 Dec; 60(12):3848-55. PubMed ID: 19950292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of rituximab in severe and mild abdominal vasculitis in the course of mixed cryoglobulinemia.
    Quartuccio L; Petrarca A; Mansutti E; Pieroni S; Calcabrini L; Avellini C; Zignego A; De Vita S
    Clin Exp Rheumatol; 2010; 28(1 Suppl 57):84-7. PubMed ID: 20412709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non HCV-Related Mixed Cryoglobulinemic Vasculitis With Biopsy-Proven Renal Involvement: The Effects of Rituximab.
    Fenoglio R; Sciascia S; Rossi D; Naretto C; Alpa M; Roccatello D
    Front Med (Lausanne); 2022; 9():819320. PubMed ID: 35419372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cryoglobulinemic vasculitis and skin ulcers. Our therapeutic strategy and review of the literature.
    Giuggioli D; Manfredi A; Lumetti F; Sebastiani M; Ferri C
    Semin Arthritis Rheum; 2015 Apr; 44(5):518-526. PubMed ID: 25547031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of rituximab in type II mixed cryoglobulinemia.
    Zaja F; De Vita S; Mazzaro C; Sacco S; Damiani D; De Marchi G; Michelutti A; Baccarani M; Fanin R; Ferraccioli G
    Blood; 2003 May; 101(10):3827-34. PubMed ID: 12560225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar).
    Vacchi C; Visentini M; Gragnani L; Fraticelli P; Tavoni A; Filippini D; Saccardo F; Lauletta G; Colantuono S; Atzeni F; Pioltelli P; Manfredi A; Casato M; Zignego AL; Monti G; Pietrogrande M; Galli M; Sebastiani M
    Intern Emerg Med; 2021 Jan; 16(1):149-156. PubMed ID: 32524338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment.
    Stasi C; Triboli E; Arena U; Urraro T; Petrarca A; Gragnani L; Laffi G; Zignego AL
    J Transl Med; 2014 Jan; 12():21. PubMed ID: 24456582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab.
    Petrarca A; Rigacci L; Monti M; Giannini C; Bernardi F; Caini P; Colagrande S; Bosi A; Laffi G; Zignego AL
    Dig Liver Dis; 2007 Sep; 39 Suppl 1():S129-33. PubMed ID: 17936214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.